NCT06377059 Early Detection of Complications During Immunotherapy for Haematological Malignancy
| NCT ID | NCT06377059 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rigshospitalet, Denmark |
| Condition | Hematologic Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-12-02 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-12-02 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Aims * To identify patients that should remain admitted in hospital for more intense surveillance because of high risk for development of clinical complications * Expand the understanding of the interactions between physiology and immunology for the design of future projects and general knowledge Hypothesis Development of a risk model based on a combination of physiological and immunological parameters can contribute to early detection of patients at risk for clinical complications after anti-cancer treatment.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Patients diagnosed with haematologic malignant disease (e.g. malignant lymphoma) * Patients scheduled for treatment with CART or BsAbs Exclusion Criteria: * Patient is pregnant * Patient has a pacemaker * Patient is allergic to one or more of the materials that the equipment consists of * Investigator deems patient not able to comply with participation in the study
Contact & Investigator
Sandra Egedie Lyby Taylor Pitter, MD
PRINCIPAL INVESTIGATOR
Rigshospitalet, Denmark
Frequently Asked Questions
Who can join the NCT06377059 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematologic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06377059 currently recruiting?
Yes, NCT06377059 is actively recruiting participants. Contact the research team at sandra.egedie.taylor.pitter@regionh.dk for enrollment information.
Where is the NCT06377059 trial being conducted?
This trial is being conducted at Copenhagen O, Denmark.
Who is sponsoring the NCT06377059 clinical trial?
NCT06377059 is sponsored by Rigshospitalet, Denmark. The principal investigator is Sandra Egedie Lyby Taylor Pitter, MD at Rigshospitalet, Denmark. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.